Medkart Introduces India's First Room-Temperature Stable Nicorandil Tablets, Enhancing Accessibility to Cardiac Care
Medkart, a leading generic medicine platform in India, proudly announces the launch of the nations most in-demand Nicorandil tablets which remain stable at room temperature. This innovation eliminates the need for cold-chain storage, reducing logistical challenges and making the medication more accessible and affordable for patients across diverse regions. The product is now available at all Medkart outlets.
Refrigeration Not Required-India's First Room-Temperature Nicorandil is here
Addressing Storage Challenges in Cardiac Medications
Nicorandil is widely prescribed for the treatment of chronic stable angina. Due to its sensitivity to temperature and humidity, its storage has traditionally required stringent cold-chain logistics. This requirement often poses significant challenges, especially in rural and semi-urban areas where maintaining cold-chain infrastructure is difficult.
Enhancing Affordability and Accessibility
Medkarts room-temperature stable Nicorandil tablets are manufactured under WHO-GMP-certified facilities, ensuring high-quality standards. By eliminating the need for refrigeration, the company significantly reduces distribution costs, allowing the medication to be priced up to 80% lower than its branded counterparts.
'Our room-stable Nicorandil is more than a product-it's an answer to India's cold chain problem in heart care,' said Ankur Agarwal, Co-founder of Medkart. 'Were proving that innovation doesnt have to be expensive-it has to be relevant.'
Dr Ramesh Mehta, a senior cardiologist based in Ahmedabad, added, 'Ensuring that a cardiac drug like Nicorandil remains effective without refrigeration is a major step forward, particularly for patients in remote regions. We've long seen efficacy compromised due to storage issues. This advancement will save lives and improve treatment consistency.'
Tackling the Cardiovascular Disease Burden
Cardiovascular diseases (CVDs) are a leading cause of mortality in India. According to the Global Burden of Disease Study, heart disease is the leading cause of death among women in India, accounting for almost 18% of all female deaths. Medkart's launch addresses both cost and accessibility in one formulation.
Product Availability
Medkart's room-stable Nicorandil tablets are now available at over 35000+ pincodes and online at www.medkart.in.
To illustrate the cost difference between branded and Medkarts generic versions of Nicorandil tablets, here's a comparative snapshot based on real-time Medkart data:
Product Type
Strength
Branded Price Per Tab (Rs.)
Medkart Price Per Tab (Rs.)
Savings (Rs.)
Savings (%)
Nicorandil 10 MG Tablet
10 mg
Rs. 26.95
Rs. 5.2
Rs. 21.75
80.72%
Nicorandil 5 MG Tablet
5 mg
Rs. 16.5
Rs. 3.1
Rs. 13.4
81.21%
*Prices are based on current Medkart data. Actual savings may vary.
About Medkart
Founded in 2014, Medkart is committed to making affordable healthcare accessible to all-especially for chronic conditions like heart disease, diabetes, and hypertension where long-term medication is critical. With a growing network of over 100+ retail outlets across India and a seamless online platform, Medkart empowers people to compare medicine prices, access WHO-GMP-certified generics, and receive reliable guidance from trained pharmacists.
Having served over 11 lakh families and facilitated savings of more than Rs. 600 crore to date, Medkart leverages a tech-first approach through tools like dosage comparison, molecule-based search, store locator, and in-app ordering. Grounded in transparency and trust, Medkart continues to redefine India's pharmaceutical ecosystem by making quality treatment affordable for all.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
United News of India
3 hours ago
- United News of India
Int'l AIDS forum kicks off in Rwanda's capital
Kigali, July 14 (UNI) The 13th International AIDS Society (IAS) Conference on HIV Science officially opened Monday in the Rwandan capital of Kigali, with a strong call to accelerate access to long-acting HIV prevention and treatment innovations amid growing global funding challenges. The event, themed "Breakthroughs amid Crisis: the Future of HIV Innovation," has convened about 4,000 participants, including global leaders, researchers, scientists, and civil society members. Speaking at the conference, Rwandan Minister of Health Sabin Nsanzimana said that Rwanda's experience in the HIV response over the past few decades demonstrates what is possible when countries prioritize people-centered approaches and invest in strategic partnerships. "We have better tools for prevention and treatment. We have better ways to engage our communities to fight stigma and discrimination, and better integration within our systems. This means we can not only achieve HIV control, but we also need to strengthen our health systems," he added. IAS President Beatriz Grinsztein underlined new World Health Organization (WHO) guidelines, groundbreaking licensing agreements, and promising research as signs that long-acting HIV prevention and treatment options are becoming more feasible for widespread use. "Our next challenge is clear: leaders must commit the funding and resources needed to integrate these scientific advances into health systems quickly and equitably so that people everywhere can benefit from these life-changing options," Grinsztejn emphasized. At the event, the WHO issued a statement announcing new guidelines that recommend using injectable lenacapavir twice a year as an additional pre-exposure prophylaxis option for HIV prevention -- a landmark policy action that could help reshape the global HIV response. "While an HIV vaccine remains elusive, lenacapavir is the next best thing: a long-acting antiretroviral shown in trials to prevent almost all HIV infections among those at risk," WHO Director-General Tedros Adhanom Ghebreyesus is quoted as saying in the statement. The IAS Conference on HIV Science is recognized as the world's most influential meeting on HIV research and its applications. Its 2025 edition, which runs until Thursday, features hundreds of sessions and presentations focused on translating scientific breakthroughs into real-world impact, with a particular emphasis on solutions for regions and populations most affected by HIV. UNI XINHUA GNK
Economic Times
3 hours ago
- Economic Times
WHO recommends Gilead's twice-yearly injection for HIV prevention
The World Health Organization on Monday recommended Gilead's lenacapavir, a twice-yearly injection, as a tool to prevent HIV infection. The recommendation, issued at the International AIDS Conference in Kigali, Rwanda, comes nearly a month after the U.S. health regulator approved the drug, giving patients new hope of interrupting virus transmission. The twice-yearly injectable offers a long-acting alternative to daily oral pills and other shorter-acting options, reshaping the response to the disease especially among those who face challenges with daily adherence, stigma, or access to health care. "While an HIV vaccine remains elusive, lenacapavir is the next best thing," said Tedros Adhanom Ghebreyesus, WHO Director-General. The WHO's recommendations come at a critical moment as HIV prevention efforts stagnate with 1.3 million new HIV infections occurring in 2024 as funding challenges, stigma around the disease persist. These infections disproportionately impact populations such as sex workers, men who have sex with men, transgender people, people who inject drugs, people in prisons, and children and has also recommended a public health approach to HIV testing using HIV rapid tests that would remove a major access barrier by eliminating complex and costly part of a class of drugs known as capsid inhibitors, proved nearly 100% effective at preventing HIV in large trials last year.
Time of India
4 hours ago
- Time of India
WHO recommends Gilead's twice-yearly injection for HIV prevention
The World Health Organization on Monday recommended Gilead 's lenacapavir , a twice-yearly injection, as a tool to prevent HIV infection . The recommendation, issued at the International AIDS Conference in Kigali, Rwanda, comes nearly a month after the U.S. health regulator approved the drug, giving patients new hope of interrupting virus transmission. The twice-yearly injectable offers a long-acting alternative to daily oral pills and other shorter-acting options, reshaping the response to the disease especially among those who face challenges with daily adherence, stigma, or access to health care. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Elegant New Scooters For Seniors In 2024: The Prices May Surprise You Mobility Scooter | Search Ads Learn More Undo "While an HIV vaccine remains elusive, lenacapavir is the next best thing," said Tedros Adhanom Ghebreyesus , WHO Director-General. The WHO's recommendations come at a critical moment as HIV prevention efforts stagnate with 1.3 million new HIV infections occurring in 2024 as funding challenges, stigma around the disease persist. Live Events These infections disproportionately impact populations such as sex workers, men who have sex with men, transgender people, people who inject drugs, people in prisons, and children and adolescents. WHO has also recommended a public health approach to HIV testing using HIV rapid tests that would remove a major access barrier by eliminating complex and costly procedures. Lenacapavir, part of a class of drugs known as capsid inhibitors, proved nearly 100% effective at preventing HIV in large trials last year.
